Prophylactic eculizumab for kidney transplantation in a child with atypical hemolytic uremic syndrome due to complement factor H mutation

Pediatric Transplantation

Volumn 18, Issue 6, 2014, Pages

  Ranch, Daniel ^a   Crowther, Barrett ^b   Arar, Mazen ^a   Assanasen, Chatchawin ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b University Hospital   (United States)

Author keywords

atypical hemolytic uremic syndrome; complement factor H; eculizumab; pediatric kidney transplantation

Indexed keywords

COMPLEMENT FACTOR H; ECULIZUMAB; MONOCLONAL ANTIBODY;

ARTICLE; CASE REPORT; CHILD; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE EXACERBATION; FEMALE; GENE MUTATION; HEMOLYTIC UREMIC SYNDROME; HUMAN; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; PROPHYLAXIS; ATYPICAL HEMOLYTIC UREMIC SYNDROME; GENETICS; MUTATION; PRESCHOOL CHILD;

ANTIBODIES, MONOCLONAL, HUMANIZED; ATYPICAL HEMOLYTIC UREMIC SYNDROME; CHILD, PRESCHOOL; COMPLEMENT FACTOR H; FEMALE; HUMANS; KIDNEY TRANSPLANTATION; MUTATION;

EID: 84906097193     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/petr.12290     Document Type: Article

References (20)

1. Caprioli J, Noris M, Brioschi S, et al. Genetics of HUS: The impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006: 108: 1267-1279.
2. Noris M, Remuzzi G,. Atypical hemolytic-uremic syndrome. N Engl J Med 2009: 361: 1676-1687.
3. Al-Akash SI, Almond PS, Savell VH Jr, Gharaybeh SI, Hogue C,. Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation. Pediatr Nephrol 2011: 26: 613-619.
4. Zimmerhackl LB, Hofer J, Cortina G, et al. Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. N Engl J Med 2010: 362: 1746-1748.
5. Weitz M, Amon O, Bassler D, Koenigsrainer A, Nadalin S,. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome. Pediatr Nephrol 2011: 26: 1325-1329.
6. Nester C, Stewart Z, Myers D, et al. Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2011: 6: 1488-1494.
7. Krid S, Roumenina LT, Beury D, Charbit M, et al. Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH/CFHR1 hybrid protein. Am J Transplant 2012: 12: 1938-1944.
8. Joszi M, Heinen S, Hartman A, et al. Factor H and atypical hemolytic uremic syndrome: Mutations in the C-terminus cause structural changes and defective recognition functions. J Am Soc Nephrol 2006: 17: 170-177.
9. Alexion Pharmaceuticals. Soliris (Eculizumab) Full Prescribing Information. Cheshire, CT: Alexion Pharmaceuticals, 2012.
10. McDonald SP, Jonathan CC,. Long-term survival of children with end-stage renal disease. N Engl J Med 2004: 350: 2654-2662.
11. Groothoff JW,. Long-term outcomes of children with end-stage renal disease. Pediatr Nephrol 2005: 20: 849-853.
12. Fitzpatrick MM, Walters MD, Trompeter RS, Dillon MJ, Barratt TM,. Atypical (non-diarrhea-associated) hemolytic-uremic syndrome in childhood. J Pediatr 1993: 122: 532-537.
13. Tran H, Chaudhuri A, Concepcion W, Grimm PC,. Use of eculizumab and plasma exchange in successful combined liver-kidney transplantation in a case of atypical HUS associated with complement factor H mutation. Pediatr Nephrol 2014: 29: 477-480.
14. Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D, Thymoglobulin Induction Study Group. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006: 355: 1967-1977.
15. Mollnes TE, Fosse E,. The complement system in trauma-related and ischemic tissue damage: A brief review. Shock 1994: 2: 301-310.
16. Xie L, Nester CM, Reed AI, Zhang Y, Smith RJ, Thomas CP,. Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: A case report. Transplant Proc 2012: 44: 3037-3040.
17. Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013: 368: 2169-2181.
18. Valoti E, Alberti M, Noris M,. Posttransplant recurrence of atypical hemolytic uremic syndrome. J Nephrol 2012: 25: 911-917.
19. Le Quintrec M, Zuber J, Moulin B, et al. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant 2013: 13: 663-675.
20. Noris M, Remuzzi G,. Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation. Curr Opin Nephrol Hypertens 2013: 22: 704-712.